Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Clinical trial NCT02875132 · COMPLETED

Trial details

NCT number: NCT02875132
Sponsor: Chinese University of Hong Kong
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acral Lentiginous Melanoma

Start date: 2017-02-15
Primary completion: 2022-02-28
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.